Protgen Ltd.
4Patents
4Active
4Granted
41Portfolio score
Filing activity: Sep 13, 2010 → Feb 13, 2015 · 1 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8389684B2 | Tumor biomarker | Emerging Cross-Sectional Technologies | 0 | Active |
| US10054590B2 | Use of nucleolin as a biomarker for lymphangiogenesis in a cancer prognosis and therapy | Physics | 0 | Active |
| US9815906B2 | Method of inhibiting or treating cancer metastasis | Emerging Cross-Sectional Technologies | 0 | Active |
| US8975030B2 | Method for cancer detection | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.